Polaryx Therapeutics, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
NASDAQ
Polaryx Therapeutics, Inc. reported the immediate resignation of its Chief Medical Officer, Lisa Bollinger, MD, on July 19, 2026.
NASDAQ
Polaryx Therapeutics, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on September 10, 2026, with a record date of July 27, 2026.
NASDAQ
Polaryx Therapeutics has closed a $10 million private placement to fund its upcoming SOTERIA Phase 2 basket trial.